Copy
NeoStem Announces Lead Investigator for Phase 3 Trial


NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma

Dr. Merrick Ross to Lead NeoStem's Phase 3 Trial of Immuno-Oncology Product Candidate NBS20

 

New York, May 26, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies, today announced the appointment of Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), as the lead principal investigator for NeoStem's Intus study. The Intus study is a Phase 3 clinical trial investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate NBS20 (USAN = eltrapuldencel-T) in patients with stage III recurrent or stage IV metastatic melanoma.

"I have dedicated my career to helping patients with cancer to live the longest, highest-quality lives they can in each individual case," said Dr. Ross. "I have seen melanoma treatments evolve over the past 30 years and am looking forward to serving as study chairman for this pivotal Phase 3 trial."

Dr. Ross is a surgical oncologist with specific expertise in melanoma who has worked and taught at MD Anderson since 1989. Dr. Ross has published extensively in medical literature, frequently lectures both domestically and abroad and has been in leadership roles for several completed melanoma clinical trials at the institutional, national, and international level. He has also been the recipient of various honors, including the Charles M. McBride Distinguished Professorship in Surgical Oncology. Dr. Ross received his medical degree from the University of Illinois School of Medicine in Chicago, completed a residency in General Surgery at the University of Illinois Affiliated Hospitals in Chicago, and was Chief Resident at the University of Illinois Department of Surgery. Additionally, Dr. Ross completed a research fellowship at Scripps Clinic and Research Institute in La Jolla, California, and a surgical oncology fellowship at The University of Texas MD Anderson Cancer Center.

"We are very fortunate to have Dr. Ross serve as the lead principal investigator for the Intus study," said Dr. Douglas Losordo, Chief Medical Officer of NeoStem. "His expertise as a surgical oncologist and experience in melanoma particularly make him an invaluable resource to the trial as we work to advance NBS20. We are delighted to welcome the leadership of this esteemed physician-scientist."

For more information on the Intus Study please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.

About NeoStem
NeoStem, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. NeoStem is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.neostem.com.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A.  Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.

 
Please visit our new service www.swiresearch.com. We would appreciate if you could pass our newsletter on to your friends and colleagues and naturally, we always appreciate your feedback and comments.
 
 
 
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site www.stockwatchindex.com, its "Rise Above The Noise" newsletter and SWI Research site www.swiresearch.com. These services provide readers with information and research on new and promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analyst reports and opinions from credible Wall Street firms that we respect and frequently sample. The weekly SWI QuickPicks  Ratings Report keeps you informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by these companies and do not necessarily hold positions in any of these stocks.  You can conveniently follow the live links for each of these stocks on http://www.stockwatchindex.com/swi-quickpicks for more detail.  SWI's periodical "Portfolio Performance Report" frequently reports about the performance of the stocks that we have purchased and may be trading in the SWI portfolio. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site www.wideworldofstocks.com.  
 
Facebook
Twitter
LinkedIn
Google +
StockWatchIndex
 
Good luck and please pass this newsletter on to a friend
to continue building our community.
 

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest.  Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp